Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

NCT07310355 is registered in ClinicalTrials.gov with Chengdu StarRay Therapeutics Co., Ltd as lead sponsor.

NCT NCT07310355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07310355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Chengdu StarRay Therapeutics Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 30, 2025
Completion date
April 30, 2030
Enrollment
49 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (mcrpc)